Cargando…

House Dust Mite Subcutaneous Immunotherapy and Lung Function Trajectory in Children and Adolescents with Asthma

Background: Allergen-specific immunotherapy is currently the only disease-modifying treatment for allergic asthma, and it has been shown to improve control of asthma while reducing both drug use and asthma exacerbations. However, its effects on lung function—especially its long-term effects—remain c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nogami, Kazutaka, Nagao, Mizuho, Takase, Takafumi, Yasuda, Yasuaki, Yamada, Shingo, Matsunaga, Mayumi, Hoshi, Miyuki, Hamada, Kana, Kuwabara, Yu, Tsugawa, Takeshi, Fujisawa, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028398/
https://www.ncbi.nlm.nih.gov/pubmed/35455531
http://dx.doi.org/10.3390/children9040487
_version_ 1784691607464837120
author Nogami, Kazutaka
Nagao, Mizuho
Takase, Takafumi
Yasuda, Yasuaki
Yamada, Shingo
Matsunaga, Mayumi
Hoshi, Miyuki
Hamada, Kana
Kuwabara, Yu
Tsugawa, Takeshi
Fujisawa, Takao
author_facet Nogami, Kazutaka
Nagao, Mizuho
Takase, Takafumi
Yasuda, Yasuaki
Yamada, Shingo
Matsunaga, Mayumi
Hoshi, Miyuki
Hamada, Kana
Kuwabara, Yu
Tsugawa, Takeshi
Fujisawa, Takao
author_sort Nogami, Kazutaka
collection PubMed
description Background: Allergen-specific immunotherapy is currently the only disease-modifying treatment for allergic asthma, and it has been shown to improve control of asthma while reducing both drug use and asthma exacerbations. However, its effects on lung function—especially its long-term effects—remain controversial. We aimed to identify factors associated with a possible beneficial effect of allergen-specific immunotherapy on lung function in asthma by retrospectively evaluating the long-term changes in lung function in children with asthma who received house dust mite subcutaneous immunotherapy (HDM-SCIT). Methods: We enrolled children with asthma who had undergone HDM-SCIT for more than 1 year. Clinical information and lung function measurements were retrieved from the electronic chart system. To characterize the trajectory of lung function change, we performed linear regression analysis to evaluate the maximal expiratory flow at 50% of the forced vital capacity during two periods: before and during HDM-SCIT. Slopes from a least-squares regression line for the two periods, i.e., S1 before HDM-SCIT and S2 during HDM-SCIT, were compared. The subjects were then classified into two groups: an improving group (Group I) defined as S2 − S1 > 0, and a declining group (Group D) defined as S2 − S1 < 0. The clinical factors at the start of HDM-SCIT were compared between the two groups. Results: A total of 16 patients were analyzed. Eight patients were classified into each of Group I and Group D. The mean ages were 10.5 and 11.8 years, and the mean treatment periods were 4.1 and 3.9 years. Group I had a significantly lower blood eosinophil count and a significantly higher HDM-specific IgE level than Group D. Logistic regression showed a strong relationship between those two markers and the lung function trajectory. Conclusion: Control of the blood eosinophil count in highly HDM-sensitized patients may increase the beneficial effect of HDM-SCIT on lung function.
format Online
Article
Text
id pubmed-9028398
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90283982022-04-23 House Dust Mite Subcutaneous Immunotherapy and Lung Function Trajectory in Children and Adolescents with Asthma Nogami, Kazutaka Nagao, Mizuho Takase, Takafumi Yasuda, Yasuaki Yamada, Shingo Matsunaga, Mayumi Hoshi, Miyuki Hamada, Kana Kuwabara, Yu Tsugawa, Takeshi Fujisawa, Takao Children (Basel) Article Background: Allergen-specific immunotherapy is currently the only disease-modifying treatment for allergic asthma, and it has been shown to improve control of asthma while reducing both drug use and asthma exacerbations. However, its effects on lung function—especially its long-term effects—remain controversial. We aimed to identify factors associated with a possible beneficial effect of allergen-specific immunotherapy on lung function in asthma by retrospectively evaluating the long-term changes in lung function in children with asthma who received house dust mite subcutaneous immunotherapy (HDM-SCIT). Methods: We enrolled children with asthma who had undergone HDM-SCIT for more than 1 year. Clinical information and lung function measurements were retrieved from the electronic chart system. To characterize the trajectory of lung function change, we performed linear regression analysis to evaluate the maximal expiratory flow at 50% of the forced vital capacity during two periods: before and during HDM-SCIT. Slopes from a least-squares regression line for the two periods, i.e., S1 before HDM-SCIT and S2 during HDM-SCIT, were compared. The subjects were then classified into two groups: an improving group (Group I) defined as S2 − S1 > 0, and a declining group (Group D) defined as S2 − S1 < 0. The clinical factors at the start of HDM-SCIT were compared between the two groups. Results: A total of 16 patients were analyzed. Eight patients were classified into each of Group I and Group D. The mean ages were 10.5 and 11.8 years, and the mean treatment periods were 4.1 and 3.9 years. Group I had a significantly lower blood eosinophil count and a significantly higher HDM-specific IgE level than Group D. Logistic regression showed a strong relationship between those two markers and the lung function trajectory. Conclusion: Control of the blood eosinophil count in highly HDM-sensitized patients may increase the beneficial effect of HDM-SCIT on lung function. MDPI 2022-04-01 /pmc/articles/PMC9028398/ /pubmed/35455531 http://dx.doi.org/10.3390/children9040487 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nogami, Kazutaka
Nagao, Mizuho
Takase, Takafumi
Yasuda, Yasuaki
Yamada, Shingo
Matsunaga, Mayumi
Hoshi, Miyuki
Hamada, Kana
Kuwabara, Yu
Tsugawa, Takeshi
Fujisawa, Takao
House Dust Mite Subcutaneous Immunotherapy and Lung Function Trajectory in Children and Adolescents with Asthma
title House Dust Mite Subcutaneous Immunotherapy and Lung Function Trajectory in Children and Adolescents with Asthma
title_full House Dust Mite Subcutaneous Immunotherapy and Lung Function Trajectory in Children and Adolescents with Asthma
title_fullStr House Dust Mite Subcutaneous Immunotherapy and Lung Function Trajectory in Children and Adolescents with Asthma
title_full_unstemmed House Dust Mite Subcutaneous Immunotherapy and Lung Function Trajectory in Children and Adolescents with Asthma
title_short House Dust Mite Subcutaneous Immunotherapy and Lung Function Trajectory in Children and Adolescents with Asthma
title_sort house dust mite subcutaneous immunotherapy and lung function trajectory in children and adolescents with asthma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028398/
https://www.ncbi.nlm.nih.gov/pubmed/35455531
http://dx.doi.org/10.3390/children9040487
work_keys_str_mv AT nogamikazutaka housedustmitesubcutaneousimmunotherapyandlungfunctiontrajectoryinchildrenandadolescentswithasthma
AT nagaomizuho housedustmitesubcutaneousimmunotherapyandlungfunctiontrajectoryinchildrenandadolescentswithasthma
AT takasetakafumi housedustmitesubcutaneousimmunotherapyandlungfunctiontrajectoryinchildrenandadolescentswithasthma
AT yasudayasuaki housedustmitesubcutaneousimmunotherapyandlungfunctiontrajectoryinchildrenandadolescentswithasthma
AT yamadashingo housedustmitesubcutaneousimmunotherapyandlungfunctiontrajectoryinchildrenandadolescentswithasthma
AT matsunagamayumi housedustmitesubcutaneousimmunotherapyandlungfunctiontrajectoryinchildrenandadolescentswithasthma
AT hoshimiyuki housedustmitesubcutaneousimmunotherapyandlungfunctiontrajectoryinchildrenandadolescentswithasthma
AT hamadakana housedustmitesubcutaneousimmunotherapyandlungfunctiontrajectoryinchildrenandadolescentswithasthma
AT kuwabarayu housedustmitesubcutaneousimmunotherapyandlungfunctiontrajectoryinchildrenandadolescentswithasthma
AT tsugawatakeshi housedustmitesubcutaneousimmunotherapyandlungfunctiontrajectoryinchildrenandadolescentswithasthma
AT fujisawatakao housedustmitesubcutaneousimmunotherapyandlungfunctiontrajectoryinchildrenandadolescentswithasthma